Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PHARMACYCLICS INC (PCYC)
|
Add to portfolio |
|
|
|
| Price: |
$56.28
| | Metrics |
| OS: |
76.8
|
B
| |
8
|
% ROE
|
| Market cap: |
$4322
|
B
| |
82
|
% ROIC
|
|
Net cash:
|
$887
|
M
| |
$0.01
|
per share
|
|
EV:
|
$4321
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$113
|
M
| |
38290.3
|
x EV/EBITDA
|
|
EBIT
|
$108
|
M
| |
40032.1
|
x EV/EBIT
|
| EPS |
$0.90
| |
62.5
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Jun-30-12 | Jun-30-11 | Apr-19-11 | Jun-30-10 | Jun-30-09 |
| Revenues | 729.7 | 260.2 | 160.7 | 82.0 | 8.2 | | 9.3 | 14.0 |
| Revenue growth | 180.5% | 61.9% | | 895.9% | -11.5% | | -33.3% | |
| Cost of goods sold | 40.4 | 3.5 | -47.5 | -54.5 | -34.5 | | -32.5 | 8.5 |
| Gross profit | 689.3 | 256.7 | 208.1 | 136.5 | 42.7 | | 41.8 | 5.5 |
| Gross margin | 94.5% | 98.7% | 129.5% | 166.5% | 518.8% | | 449.0% | 39.3% |
| Selling, general and administrative | 168.0 | 104.0 | 12.1 | 15.6 | 9.1 | | | |
| Research and development | 344.9 | 256.0 | 76.0 | 109.1 | 69.0 | | 17.4 | |
| General and administrative | | | | | | | 15.1 | 8.5 |
| EBITA | 122.9 | 97.9 | 120.1 | 11.9 | -35.4 | | -15.6 | -22.4 |
| EBITA margin | 16.8% | 37.6% | 74.7% | 14.5% | -429.7% | | -167.7% | -160.7% |
| Amortization of intangibles | 0.5 | | | | | | | |
| EBIT | 122.4 | 97.9 | 120.1 | 11.9 | -35.4 | | -15.6 | -22.4 |
| EBIT margin | 16.8% | 37.6% | 74.7% | 14.5% | -429.7% | | -167.7% | -160.7% |
| Pre-tax income | 122.4 | 98.1 | 120.2 | 12.0 | -35.2 | | -15.6 | -22.9 |
| Income taxes | 36.3 | 31.1 | 2.6 | 0.0 | 0.0 | | -0.6 | 0.6 |
| Tax rate | 29.7% | 31.7% | 2.2% | 0.3% | 0.0% | | 3.5% | |
| Net income | 86.1 | 67.0 | 117.5 | 12.0 | -35.2 | | -15.0 | -23.4 |
| Net margin | 11.8% | 25.8% | 73.2% | 14.6% | -427.6% | | -161.4% | -168.0% |
| |
| Diluted EPS | $1.10 | $0.87 | $1.58 | $0.17 | ($0.59) | | ($0.31) | ($0.88) |
| Shares outstanding (diluted) | 78.2 | 77.1 | 74.4 | 72.6 | 60.0 | | 48.3 | 26.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|